Meeting
2021 ASCO Annual Meeting
Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.
Authors
Davina Gale
Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
Davina Gale , Katrin Heider , Malcolm Perry , Giovanni Marsico , Andrea Ruiz-Valdepeñas , Viona Rundell , Jerome Wulff , Garima Sharma , Karen Howarth , David Gilligan , Susan Harden , Doris M. Rassl , Robert Rintoul , Nitzan Rosenfeld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04153526
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8517)
DOI
10.1200/JCO.2021.39.15_suppl.8517
Abstract #
8517
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer.
First Author: Milou Schuurbiers
Poster
2022 ASCO Annual Meeting
Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.
First Author: Rong Yin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
First Author: Susanna Slater
Poster
2022 ASCO Annual Meeting
Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with early-stage non–small cell lung cancer after surgery.
First Author: Ning Li